TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ALT improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: AST improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: clinical score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary iodine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum total bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: blood urea nitrogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total OMAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for oral antifungal agents
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum LDL cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Small-dense LDL (sd-LDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: gene-resistant mutation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiplaque effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: >3% BMD responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global quality of life (QOL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quality of work score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: pain with urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognition test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain ratings after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of stay in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Opioid consumption before discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite events
Endpoint domain: Mortality/survival
Primary endpoint: self-reports of 'high'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of hamstring strain-injuries
Endpoint domain: Adverse events/effects
Primary endpoint: HAM-D improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion visualization and delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival of BM at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death from BM
Endpoint domain: Mortality/survival
Primary endpoint: Renal problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrent urinary tract problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LV untwisting rate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in arterial occlusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rating of Perceived Exertion (RPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of self-management measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Partner pregnant rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sperm count and viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean reduction in hairs of diameter > 40 microm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in total number of new hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in scalp seborrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated frequencies of sperm aneuploidy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: reduced linearity of sperm motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: fewer motile sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: remission at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic remission at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on psychometric self-report scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achievement of higher levels in the BAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transtricuspid systolic pressure gradient (RVTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Estimated median overall survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Least-square mean reduction in SBP at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident MI or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants' self confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Key communication behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental abrasion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvements in DAS28‐CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INR AUC(0-168 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics of Apricitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum glycocholic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Transaminase levels
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Left Ventricular Mass (LVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: foot tap time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensibility scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early mortality within 21 days
Endpoint domain: Mortality/survival
Primary endpoint: Risk of developing tooth sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total body weight (TBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean CFF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subcutaneous adipose tissue (SAT) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse drug events rate
Endpoint domain: Adverse events/effects
Primary endpoint: close-call rate
Endpoint domain: Adverse events/effects
Primary endpoint: amount of fentanyl required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uninterrupted hemodynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of metabolites and hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic remission at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of ulcers at week 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic response and remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term survival rate
Endpoint domain: Mortality/survival
Primary endpoint: ratios of recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: auditory-verbal manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual-spatial manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of accelerations of 10 beats per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time spent in episodes of high variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in cartilage degradation biomarker CTX-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite gastrointestinal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: primary gastrointestinal endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Angiographic late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Target lesion revascularization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bleaching effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supplementary dose of local anesthetic
Endpoint domain: Adverse events/effects
Primary endpoint: FIM 'sphincter' function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM 'communication' function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM 'cognition' function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear-film osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSDI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bulbar hyperemia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy rate of identifying abnormal findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed confidence in physical examination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-vaccination HI geometric mean titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited erythema and induration
Endpoint domain: Adverse events/effects
Primary endpoint: Mean TT power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to infinity (AUC(0-infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to tau (AUC(0-tau))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fetal scalp blood sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Training completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAS outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: caregiver burden score
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Conjunctival symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance P levels in tear fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma vWF antigen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma TM level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: lower-leg growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binary restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of hematoma surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hospital cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: high-sensitivity TNF-α (hs-TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble tumor necrosis factor receptor (sTNF-R2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 4-hydroxy-2-nonenal (4-HNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transfusion savings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in PHQ-9 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate for sensory nerve disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart failure rates
Endpoint domain: Mortality/survival
Primary endpoint: Combined cardiovascular disease rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological benefits (balance, nervousness, strength, appearance satisfaction)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum serotonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of developing Alzheimer's disease
Endpoint domain: Mortality/survival
Primary endpoint: HbA1c decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk for hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived chewing ability of hard foods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with denture functions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: geriatric depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: vigour
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: hypersomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of NB-UVB irradiations required for positive clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hair and nails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibreoptic intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall response to chemoradiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative risk of heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Relative risk of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolite differences between vitamin D3 and placebo treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Good outcome (modified Ranking Scale, 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Poor outcome (modified Ranking Scale, 4-6)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to reach <35.5°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of HRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in circulatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of patients with LDL < 100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average cost per patient to the healthcare system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fewer hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increased intention to increase level of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of cartilage repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of primary endpoint events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in heart functional class NYHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QIDS-SR16
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Q-LES-Q-SF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological profiles indicative of cortical delays/immaturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: High-frequency power (beta, 12-20 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline BARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI‐I responder analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-diastolic velocity (EDV) in the OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistivity index (RI) in the OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: transoxygenator resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prothrombin F1.2 fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: beta-thromboglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean increase of heart rate after atropine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from the basal heart rate to the IHRo after TAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognition (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported QoL (QoL-AD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General health status (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain scores at rest and on movement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: LFI score change over 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: bacterial contamination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Efficacy of fever detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation success rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SAT density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAT area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes